Nektar Therapeutics

Covx Technologies Ireland Limited

Pfizer Corporation

Haim Moskowitz

Mary J Bossard

Yujun Wang

Xiaofeng Liu

Steven O Roczniak

Ping Zhang

Mark John Pozzo

Palani Balu

C Simone Jude-Fishburn

Harold Zappe

Rory Francis Finn

Cherie F Ali

Dennis G Fry

Dawei Sheng

Olivier Alexandre Laurent

Jin Xie

Christine Taylor Brew

Jie Huang

Nancy Jane Levin

Moorthy Sitharamaiah Suriyanarayana Palanki

Nicholas Gary Luksha

Joseph Patrick Martin, Jr

Gregory Allan Waszak

Elizabeth Louise Minamitani

Gopinath Vedachalam Annathur

Christine Brew

Elizabeth Minamitani

The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.

Polymer conjugates of protegrin peptides

Polymer conjugates of therapeutic peptides

The present invention provides a composition of the formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Anti-diabetic compounds

Growing community of inventors

San Diego, CA, United States of America

Haim Moskowitz